Search results
Results from the WOW.Com Content Network
Tissue factor pathway inhibitor (or TFPI) is a single-chain polypeptide which can reversibly inhibit factor Xa (Xa). While Xa is inhibited, the Xa-TFPI complex can subsequently also inhibit the FVIIa-tissue factor complex. TFPI contributes significantly to the inhibition of Xa in vivo, despite being present at concentrations of only 2.5 nM.
[1] [4] [2] It is a tissue factor pathway inhibitor (TFPI) antagonist. [4] It was developed by Pfizer. [5] Marstacimab is a new type of medication that, rather than replacing a clotting factor, works by reducing the amount, and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor. [4]
21789 Ensembl ENSG00000105825 ENSMUSG00000029664 UniProt P48307 O35536 RefSeq (mRNA) NM_006528 NM_001271003 NM_001271004 NM_009364 NM_001381907 NM_001381908 RefSeq (protein) NP_001257932 NP_001257933 NP_006519 NP_033390 NP_001368836 NP_001368837 Location (UCSC) Chr 7: 93.89 – 93.89 Mb Chr 6: 3.96 – 3.99 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Tissue factor pathway ...
Examples of Kunitz-type protease inhibitors are aprotinin (bovine pancreatic trypsin inhibitor, BPTI), Alzheimer's amyloid precursor protein (APP), and tissue factor pathway inhibitor (TFPI). Kunitz STI protease inhibitor, the trypsin inhibitor initially studied by Moses Kunitz, was extracted from soybeans.
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered ...
tissue factor pathway inhibitor (TFPI) Y: bleeding with hemophilia: Maslimomab: mouse: T-cell receptor: Mavrilimumab [38] mab: human: GMCSF receptor α-chain: rheumatoid arthritis: Matuzumab [24] mab: humanized: Epidermal growth factor receptor (EGFR) colorectal, lung and stomach cancer Mepolizumab [47] Bosatria: mab: humanized: IL-5: Y: asthma ...
The efficacy and safety of concizumab were evaluated in a multi-national, multi-center, open-label, phase III trial (NCT04083781) with 91 adult and 42 adolescent male participants with hemophilia A or B with inhibitors who have been prescribed, or are in need of, treatment with therapies that bypass the inhibitor effect.
Antithrombin is a serine protease inhibitor that degrades the serine proteases: thrombin, FIXa, FXa, FXIa, and FXIIa. It is constantly active, but its adhesion to these factors is increased by the presence of heparan sulfate (a glycosaminoglycan ) or the administration of heparins (different heparinoids increase affinity to FXa, thrombin, or both).